Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 49
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Atopic Dermatitis
Interventions: Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: ABBV-969; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Chronic Migraine
Interventions: Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg, NX-13 750mg, NX-13 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more

Conditions: Major Depressive Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions: Paricalcitol; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 9 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 14
States / cities: Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more

Conditions: Stroke
Interventions: Screener, Standard of care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometriosis
Interventions: Elagolix, Placebo, Combined Oral Contraceptive; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 176
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine, Venetoclax, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Exocrine Pancreatic Insufficiency
Interventions: Pancrelipase Capsules; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more

Conditions: Mantle Cell Lymphoma
Interventions: Venetoclax Oral Tablet [Venclexta]; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 60 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Reduce Inefficiencies in Management of Spasticity

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

About this AbbVie sponsor directory page